Bayer Lifts 2026 Full-Year Profit Outlook After Pharma Unit Beats Expectations in Q3

Bayer AG raised its 2026 full-year earnings outlook on Tuesday after a stronger-than-expected performance from its pharmaceutical division helped offset headwinds at its crop science and consumer health businesses. The German life sciences group now targets adjusted EBITDA of between 9.8 billion euros and 10.3 billion euros for the year, up from a prior forecast range of 9.6 billion euros to 10.1 billion euros. The company also lifted its free cash flow guidance for the year.

The pharmaceutical recovery was driven by robust demand for key drugs, which powered Q3 sales and EBITDA results that beat analyst estimates. Bayer's crop science and consumer health divisions continued to face market pressure, but the pharma rebound was sufficient to lift group-level expectations. The guidance upgrade marks a meaningful step in CEO Bill Anderson's broader turnaround effort, which has centered on cutting management layers and accelerating decision-making across the organization.